Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-02
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Fig Kaplan Meier K

    2022-09-16


    Fig 1. Kaplan-Meier (K-M) survival curves for (A) all esophageal squa-mous cell carcinoma (SCC) patients,
    (B) clinical stage I patients, (C) clin-ical stage II patients, and (D) clinical stage III patients stratified based on treatment with definitive chemo-radiotherapy (CRT) versus esoph-agectomy (p < 0.0001 for all).
    Fig 2. Kaplan-Meier (K-M) survival
    curves for (A) all esophageal SCC
    and (D) clinical stage III patients (p ¼
    definitive chemoradiotherapy (CRT)
    versus esophagectomy after propensity
    matching. 
    GENERAL THORACIC
    THORACIC  1064 WANG ET AL Ann Thorac Surg
    GENERAL  were 26.14% and 46.17%, respectively (p < 0.001, Table 2). The overall survival curve of the unmatched patients according to clinical stage was stratified by treatment strategy (Fig 1). The survival curve of the unmatched patients is shown in Figure 1A. Patients treated with esophagectomy alone had a significantly superior 3-year overall survival rate (p < 0.0001). The survival curve Vorinostat was assessed according to clinical stage, and for clinical stages I, II, and III, respectively, the overall survival rate of patients receiving esoph-agectomy alone was better than that Vorinostat of patients treated by definitive CRT (p < 0.001, Figs 1B–D).
    The overall survival rates of matched patients are shown in Figure 2. When patients were divided into different clinical stages, the overall survival rate in pa-tients undergoing esophagectomy alone was higher in clinical stages I and II. Analysis of the propensity-matched clinical stage III patients demonstrated that there was no significant difference between the two groups (p ¼ 0.2455, Fig 2D).  Univariate survival analysis for unmatched patients identified sex, clinical T, clinical N, clinical stage, grade, location, length, and treatment modality as prognostic factors. Regarding univariate survival analysis for matched patients, Charlson score, clinical T, clinical N, clinical stage, tumor length, and treatment modality were identified as the prognostic factors (Table 3).
    In multivariate analysis, sex, Charlson score, clinical T, clinical N, clinical stage, grade, tumor location, tumor length, and treatment modality were predictors of overall survival. Multivariate analysis after propensity score matching demonstrated microsporangia sex, Charlson score, clinical T, clinical N, grade, tumor length, and treatment modality remained the prognostic factors (Table 4).
    Comment
    We investigated the overall survival of patients with locoregional esophageal SCC who were treated with definitive CRT or esophagectomy alone in Taiwan. The
    Table 3. Univariate Analysis for All Patients Before and After Propensity Matching
    All Patients
    Propensity-Matched Patients
    Characteristics HR 95% CI p Value HR 95% CI p Value
    Male 1
    Well differentiated/ moderately differentiated 1
    Upper 1
    Definitive chemoradiotherapy 1
    CI ¼ confidence interval; HR ¼ hazard ratio.
    Ann Thorac Surg
    ESOPHAGECTOMY IN ESOPHAGEAL CANCER
    Table 4. Multivariate Analysis for All Patients Before and After Propensity Matching
    All Patients
    Propensity-Matched Patients
    Characteristics
    Age (years)
    Sex
    Male
    Female
    Charlson score
    Clinical T
    Clinical N
    Clinical stage
    I
    II
    III
    Grade
    Well/moderately differentiated 1
    Tumor location
    Upper
    Lower
    Middle
    Tumor length
    Treatment modality
    Definitive chemoradiotherapy 1
    Esophagectomy
    AHR ¼ adjusted hazard ratio; CI ¼ confidence interval.